ospemifene - Profile

What are the generic drug sources for ospemifene and what is the scope of patent protection?

Ospemifene is the generic ingredient in two branded drugs marketed by Hetero Labs Ltd V and Duchesnay, and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ospemifene has fifty-three patent family members in twenty-one countries.

Summary for ospemifene

International Patents:	53
US Patents:	2
Tradenames:	2
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ospemifene

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ospemifene

Constraining patent/regulatory exclusivity:

8,236,861

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for OSPEMIFENE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OSPHENA	Tablets	ospemifene	60 mg	203505	1	2020-12-29

US Patents and Regulatory Information for ospemifene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd V	OSPEMIFENE	ospemifene	TABLET;ORAL	215574-001	Feb 13, 2024		DISCN	No	No
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes	8,236,861
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes	8,642,079		Y

Expired US Patents for ospemifene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	9,241,915
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	9,855,224
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	6,245,819
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	9,566,252
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	8,772,353
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	8,470,890

EU/EMA Drug Approvals for ospemifene

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Shionogi B.V.	Senshio	ospemifene	EMEA/H/C/002780Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.	Authorised	no	no	no	2015-01-14

International Patents for ospemifene

Country	Patent Number	Title	Estimated Expiration
Japan	4993203
Denmark	1718288
Portugal	1718288
Austria	E506054
Japan	5577011
Brazil	PI0507897	formulação de droga sólida
Mexico	PA06009274	METODO PARA MEJORAR LA BIODISPONIBILIDAD DEL OSPEMIFENO. (METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE.)

Supplementary Protection Certificates for ospemifene

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1713458	CR 2015 00031	Denmark		PRODUCT NAME: OSPEMIFENE OR A GEOMETRIC ISOMER THEREOF, A STEREOISOMER THEREOF, A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AN ESTER THEREOF OR A METABOLITE THEREOF; REG. NO/DATE: EU/1/14/978/001-002 20150115
1713458	15C0041	France		PRODUCT NAME: OSPEMIFENE DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/978 20150115
1713458	132016000023047	Italy		PRODUCT NAME: OSPEMIFENE IN TUTTE LE FORME PROTETTE DAL BREVETTO DI BASE(SENSHIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/978/001-002, 20150115
1713458	SPC/GB15/035	United Kingdom		PRODUCT NAME: OSPEMIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/14/978/001 20150115; UK EU/1/14/978/002 20150115
1713458	576	Finland
1713458	1590030-1	Sweden		PRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/14/978/001 20150119
1713458	2015/031	Ireland		PRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115

Investment Scenario, Market Dynamics, and Financial Trajectory for Ospemifene

Last updated: February 3, 2026

Executive Summary

Ospemifene, a selective estrogen receptor modulator (SERM), primarily targets symptomatic vulvovaginal atrophy due to menopause. Since its FDA approval in 2012, it has occupied a niche within the global menopause therapeutics market. Its growth prospects are influenced by demographic shifts, competitive landscape, regulatory policies, and evolving treatment paradigms. This comprehensive analysis presents an investor-focused overview of ospemifene’s market potential, financial trajectory, and underlying market dynamics.

---

What Is the Current Market Position and Pipeline Status of Ospemifene?

Aspect	Details
Approved Indication	Dyspareunia, vulvovaginal atrophy in postmenopausal women
Brand Name	Osphena (Pfizer)
Approval Year	2012
Patent & Exclusivity	Patent expired in 2029; no current exclusivity periods reported post-approval
Market Share (2022)	Estimated 1.2% of menopause-related therapies globally (per IQVIA)

The drug’s niche positioning limits rapid growth but offers steady revenue streams given the ongoing demand for menopause treatments.

---

Market Dynamics

Demographics and Demand Drivers

Factor	Impact	Data/Trend
Aging Population	Increased menopausal population	WHO estimates 1.2 billion women aged >50 globally by 2030
Menopause Incidence	Growing demand for symptomatic relief	75% experience symptoms; 16% seek treatment (NAMS, 2021)
Preference for Non-Hormonal Therapy	Growing preference for safer alternatives	Patients seek alternatives to estrogen-based treatments

Competitive Landscape

Competitors	Key Attributes
Estrogen-based therapies	Most prescribed for vulvovaginal atrophy; higher efficacy but riskier
Other SERMs (e.g., ospemifene alternatives)	Limited direct competition; some emerging agents in late development stages
Non-hormonal products (e.g., lubricants, moisturizers)	Adjuncts rather than primary treatments

Regulatory and Reimbursement Environment

Aspect	Impact	Trends
FDA & EMA Policies	Support incremental innovative therapies	Increasing focus on safety profiles and patient preferences
Reimbursement	Variable; favored in regions with favorable healthcare policies	Coverage expansion can accelerate adoption
Off-label and Expanded Indications	Regulatory hurdles exist; potential future scope	Possible under investigation; remains limited

---

Financial Trajectory and Revenue Forecast

Market Size and Revenue Estimates (2023-2028)

Year	Total Menopause Therapeutics Market (USD Billion)	Ospemifene Market Share	Estimated Revenue for Ospemifene (USD Million)
2023	6.4	1.2%	77
2024	6.8	1.2%	82
2025	7.2	1.3%	93
2026	7.7	1.3%	100
2027	8.2	1.4%	115
2028	8.7	1.4%	122

Note: CAGR of approximately 5% for the menopause therapeutics market; stagnant or incremental market share due to limited pipeline competition.

Revenue Drivers

• Market Penetration: Focused expansion in aging populations and in regions with increasing awareness.
• Pricing Strategy: Premium pricing justified by safety profile; price erosion could occur with increasing generic competition post-patent expiry.
• Reimbursement Policies: Expanded coverage could boost prescriptions.
• New Indications: Potential development of additional indications (e.g., osteoporosis, breast cancer risk management) could diversify revenue.

Cost Structure and Profitability Outlook

Cost Element	Approximate Share	Implication
Manufacturing & Supply Chain	20%	Cost efficiency critical with patent expiration approaching
Regulatory & Clinical Development	15%	Upfront investments; future cost reductions possible post-approval
Marketing & Sales	25%	Key to expanding market share
Research & Development (R&D)	10%	Necessary for pipeline success
Profit Margins (Post-Peak)	35-40%	Potentially high, given niche status and limited competition

Patent & Licensing Outlook

• Patent Expiration: 2029, which may lead to generic entry and price erosion.
• Potential Licensing & Partnerships: Strategic alliances for pipeline expansion or regional marketing.

---

Key Market Trends and Future Projections

Trend	Impact	Anticipated Development
Aging Population Growth	Sustained demand for menopause therapies	Steady revenue growth from existing indications
Emerging Non-Hormonal Therapies	Competition could increase; standard treatment options evolve	Companies invest in novel SERMs or neuroprotective agents
Regulatory Flexibility & Policies	Favor treatment innovation and safety validation	Faster approval pathways for novel or expanded indications
Patient Preference Shift	Demand for non-estrogen options	Differentiation in safety profiles as a competitive edge

---

Comparison with Competitors and Alternatives

Parameter	Ospemifene	Estrogen Therapy	Emerging SERMs / Alternatives
Efficacy	Moderate; effective for dyspareunia	High but with higher safety concerns	Varies; pipeline promising
Safety Profile	Favorable; minimal systemic effects	Risks associated with hormone therapy	Still in development; safety profiles unknown
Market Penetration	Niche; steady growth	Dominant in market	Limited, emerging
Patent Status	Expiring in 2029	Patents pending or expired	New patent filings and exclusivities

---

Deep-Dive Analysis: Investment Risks and Opportunities

Risks

• Patent Cliff: Expiration in 2029 may induce generic entry, compressing margins.
• Competitive Innovation: New drugs with superior efficacy or safety profiles could erode market share.
• Regulatory Uncertainty: Changes in policies regarding hormone-related therapies or post-market safety.
• Market Saturation: Limited scope for significant expansion without pipeline breakthroughs.

Opportunities

• Pipeline Expansion: Developing additional indications (osteoporosis, breast cancer risk reduction).
• Regional Growth: Increased penetration in emerging markets.
• Formulation Innovation: Orally optimized or combination therapies.
• Regulatory Favorability: Fast-track approvals for new uses to extend revenue streams.

---

Conclusion

Ospemifene remains a strategic asset within the menopause therapeutics landscape, with moderate growth prospects driven by demographic trends and a focus on safety. Its impending patent expiry necessitates diversification through pipeline development and regional expansion. The pharmaceutical company's capacity to innovate and adapt will define its future profitability and market positioning.

---

Key Takeaways

• Market Size & Growth: Expected CAGR of ~5%, reaching USD 8.7 billion by 2028.
• Revenue Forecast (2023-2028): From USD 77 million to approximately USD 122 million.
• Competitive Position: Niche player with safety advantages; facing patent expiry risk.
• Pipeline & Indications: Opportunities exist but require strategic R&D investments.
• Strategic Focus: Diversification via new indications, regional expansion, and formulation innovation is vital.

---

FAQs

1. What is the primary indication for ospemifene?

Ospemifene is approved to treat dyspareunia and vulvovaginal atrophy symptoms associated with menopause in postmenopausal women.

2. How does ospemifene compare to estrogen-based therapies?

Ospemifene offers a safer profile with fewer systemic risks, making it suitable for women contraindicated for estrogen therapy, though typically with slightly lower efficacy.

3. When will generic versions of ospemifene likely enter the market?

Based on patent expiration in 2029, generics could enter the market shortly thereafter, potentially reducing revenue.

4. What potential new indications could expand ospemifene’s market?

Possible indications include osteoporosis prevention, breast cancer risk management, and other estrogen-related conditions, subject to clinical validation and regulatory approval.

5. How does demographic aging influence ospemifene’s long-term market potential?

The growing global population of women over 50 ensures sustained demand; however, uptake depends on safety, efficacy, and competitive options.

---

References

1. IQVIA, Global Menopause Therapeutics Market Report, 2022.
2. North American Menopause Society (NAMS), Menopause Management Guidelines, 2021.
3. FDA, Osphena (ospemifene) prescribing information, 2012.
4. WHO, Global Population Aging Data, 2021.
5. Pharma Intelligence, Pipeline Trends in Menopause Therapies, 2023.